Share: A minimally invasive outpatient procedure may help people avoid regaining weight after stopping popular medications like Ozempic and semaglutide, according to research being presented at Digestive Disease Week (DDW) 2026
Both are once-weekly GLP-1 receptor agonists approved for type 2 diabetes, but they are different molecules with different efficacy and side effect profiles
Li YB, Fu Q, Guo M et al (2024) MicroRNAs: pioneering regulators in Alzheimers disease pathogenesis, diagnosis, and therapy
Treatment typically begins with a low starting dose , which is gradually increased every 14 weeks (depending on the agent) until the target maintenance dose is reached or the maximum tolerated dose is achieved
Semaglutide is a compounded GLP-1 medication and the active ingredient in Rybelsus, Ozempic and Wegovy
In rats, more severe effects were seen after maternal exposure to semaglutide in the form of visceral abnormalities and major skeletal malformations ( Table 1 )